57978-48-0

Upstream product

• 100-74-3 N-ethylmorpholine; 
• 142-71-2 copper diacetate 
• 97510-86-6 potassium 2-chloro-nicotinate 
• 99-09-2 3-nitro-aniline 
• 2942-59-8 2-chloronicotinic acid 

Downstream Products

• 1227852-10-9 C₁₈H₁₅N₅O₃ 
• 152814-89-6 1-(3-nitrophenyl)-3-(4-pyridylmethyl)-1,2,3,4-tetrahydropyrido(2,3-d)pyrimidine-2,4-dione 
• 56738-76-2 1-(3-nitrophenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 152815-27-5 1-(3-Nitrophenyl)-3-(4-pyridyl-N-oxide-methyl)pyrido [2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 152815-02-6 1-(3-nitrophenyl)-3-(pyridin-3-ylmethyl)pyrido[2,3-d]-pyrimidine-2,4(1H,3H)-dione 
• 152815-26-4 1-(3-aminophenyl)-3-(pyridin-4-ylmethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 59398-66-2 3-benzyl-1-(3-nitro-phenyl)-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-2-one 
• 59361-55-6 1-(3-nitro-phenyl)-3,4-dihydro-1H-pyrido[2,3-d]pyrimidin-2-one 
• 152815-12-8 2-(3-nitroanilino)-3-aminomethylpyridine 
• 51085-35-9 2-(3-nitroanilino)-3-carbamoylpyridine 

Relevant academic research and scientific papers

Hypoxia-selective antitumor agents derived from 1,9-diazaanthracene

The nitroacridine derivative 9-[3-(N,N-dimethylamino)propylamino]- 1-nitroacridine (nitracrine) is a potent hypoxia-selective cytotoxin for tumor cells in culture. Modifications of the acridine ring result in altered DNA binding properties. This has sugge

PDE4 INHIBITORS SELECTIVE FOR THE LONG FORM OF PDE4 FOR TREATING INFLAMMATION AND AVOIDING SIDE EFFECTS

The present invention relates to compounds which are inhibitors of phosphodiesterase-4 (PDE4) useful for the treatment and prevention of stroke, myocardial infarct, cardiovascular inflammatory diseases and disorders and central nervous system disorders, t

Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones

The present invention relates to optionally substituted pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones or optionally substituted pyrido[2,3-d]pyrimidine-2(1H,3H)-ones, i.e., compounds of Formula I: STR1 wherein: Y is --CH2 -- or --C(O)--; R1 is hydrogen or --(CH2)n --R7, wherein: R7 is aryl or heteroaryl, and n is 1 or 2, provided that when Y is --C(O)--, R7 is heteroaryl; and R2, R3, R4, R5 and R6 are hydrogen, or one is selected from lower alkyl, halo, carboxy, methoxycarbonyl, carbamoyl, methylcarbamoyl, di-methylcarbamoyl, methylcarbonyl, methylthio, methylsulfinyl, methylsulfonyl, hydroxymethyl, amino, trifluoromethyl, cyano or nitro; or R2, R3, R4 and R5 are independently selected from hydrogen, lower alkyl, nitro, chloro, fluoro, methoxycarbonyl or methylcarbonyl, provided at least one is hydrogen, and R6 is hydrogen; or a pharmaceutically acceptable ester, ether or salt thereof.